TerminatedPhase 1ketamine

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

NCT ID

NCT01130909

Target Enrollment

36 participants

Start Date

2010-05

Est. Completion

2011-01

About This Study

This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.

Conditions Studied

Healthy

Interventions

•AZD6765
•AZD6765
•Ketamine
•Placebo

Eligibility

Sex:MALE

Age:30 Years - 45 Years

Healthy Volunteers:Yes

View full eligibility criteria

Inclusion Criteria:

* BMI 18-30 Non-smoker for at least 4 weeks

Exclusion Criteria:

* Any clinically relevant acute or chronic disease
* History of substance abuse Hypersensitivity to ketamine

Study Locations (1)

Research Site

Rouffach, France